Suicide Risk clinical trials

Explore recruiting suicide risk clinical trials.

Recruiting suicide risk studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Suicide Risk trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Advancing PRecise Interventions for resistant DEpression: rebalancing brain networks and investigating the trajectories of antidepressant effect with psilocybin and personalized neuromodulation (PRIDE)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Cerebral neuroinflammation during major depressive episode: multicentric comparative study (InflaDep)

France

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 2a, multi centric, open label clinical study to explore the safety and tolerability, the pharmacokinetics and pharmacodynamics profile and first signs of efficacy of PTI5803 administered as adjunctive therapy with a 3-dose escalation regimen in patients >= 14 years of age with drug-resistant seizures associated to focal cortical dysplasia, followed by an optional open-label extension study.

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy (X-TOLE4)

Spain, Portugal, Czechia, Hungary, Poland, Italy +10 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Propranolol for early secondary prevention of post-traumatic stress disorder in female victims of sexual violence: a single-center, randomized, placebo-controlled pilot study - PPRESVISE

France

Therapeutic exploratory (Phase II) EU CTIS Study details

MOODBOOSTER« Early efficacy of ketamine compared to placebo, in add-on therapy of venlafaxine for inpatients with severe unipolar major depressive episodes: a double blind randomized controlled trial »

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Suicide Risk trials by city

Suicide Risk in Toronto Suicide Risk in Vancouver Suicide Risk in Montreal Suicide Risk in Calgary Suicide Risk in Edmonton Suicide Risk in Ottawa Suicide Risk in Winnipeg Suicide Risk in Quebec City Suicide Risk in Hamilton Suicide Risk in Kitchener Suicide Risk in London Suicide Risk in Halifax Suicide Risk in New York Suicide Risk in Los Angeles Suicide Risk in Chicago Suicide Risk in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease